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Artery tertiary lymphoid organs (ATLOs) are atherosclerosis-associated lymphoid 
aggregates with varying degrees of complexity ranging from small T/B-cell clusters to 
well-structured lymph node-like though unencapsulated lymphoid tissues. ATLOs arise 
in the connective tissue that surrounds diseased arteries, i.e., the adventitia. ATLOs have 
been identified in aged atherosclerosis-prone hyperlipidemic apolipoprotein E-deficient 
(ApoE−/−) mice: they are organized into distinct immune cell compartments, including 
separate T-cell areas, activated B-cell follicles, and plasma cell niches. Analyses of ATLO 
immune cell subsets indicate antigen-specific T- and B-cell immune reactions within 
the atherosclerotic arterial wall adventitia. Moreover, ATLOs harbor innate immune cells, 
including a large component of inflammatory macrophages, B-1 cells, and an aberrant 
set of antigen-presenting cells. There is marked neoangiogenesis, irregular lymphangio-
genesis, neoformation of high endothelial venules, and de novo synthesis of lymph node-
like conduits. Molecular mechanisms of ATLO formation remain to be identified though 
media vascular smooth muscle cells may adopt features of lymphoid tissue  organizer-like 
cells by expressing lymphorganogenic chemokines, i.e., CXCL13 and CCL21. Although 
these data are consistent with the view that ATLOs participate in primary T- and B-cell 
responses against elusive atherosclerosis-specific autoantigens, their specific protective 
or disease-promoting roles remain to be identified. In this review, we discuss what is 
currently known about ATLOs and their potential impact on atherosclerosis and make 
attempts to define challenges ahead.
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ATHeROSCLeROSiS
Atherosclerosis leading to cardiovascular diseases is the major cause of death worldwide (1–8). 
The pathological hallmark of atherosclerosis is the atherosclerotic plaque in the intima layer of 
the arterial wall. Plaques ultimately clog the artery with life-threatening consequences, resulting 
in tissue infarcts such as myocardial infarcts (heart attacks) and stroke (9). Little is known about 
molecular mechanisms of atherosclerosis. Health organizations have proposed recommendations 
regarding risk factor reduction (smoking, diabetes mellitus, obesity, hypertension, hyperlipidemia, 
and sedentary lifestyle). The most important, but least understood, risk factor is aging. However, 
there is currently no clue as to the mechanisms of its impact on atherosclerosis progression. 
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A  generally accepted hypothesis is that the immune system is 
critically involved in the pathogenesis of atherosclerosis, but 
major issues of atherosclerosis immunity remain to be addressed: 
it is not clear where and when atherosclerosis-specific immune 
responses are organized; what are the relative contributions of the 
innate vis-à-vis the adaptive immune systems during the various 
stages of the disease; and, most importantly, is atherosclerosis a 
bona fide antigen-dependent autoimmune disease or a chronic 
autoinflammatory condition? Answers to these questions are 
needed to develop therapeutic strategies to directly target the 
atherosclerotic plaque in the intima of arteries.
iMMUNe HYPOTHeSiS OF 
ATHeROSCLeROSiS
Each innate and adaptive immune cell lineage and their subtypes 
has been implicated in the pathogenesis of atherosclerosis 
including platelets, neutrophils, monocytes/macrophages, mast 
cells, various dendritic cell (DC) subsets, numerous T- and B-cell 
subtypes, and innate lymphoid cells (3, 4, 7, 10–22). However, 
there is no generally accepted concept which immune cells trigger 
the disease, at which step distinct subsets promote or attenuate 
the disease, and how plaque growth unfolds at the molecular 
level. Indeed, widely different hypotheses have been proposed 
[reviewed in Ref. (23)].
Concepts regarding atherogenesis have been deduced from 
observations in mouse models including low-density lipoprotein 
receptor-deficient (LDLR−/−) or apolipoprotein E-deficient 
(ApoE−/−) mice (24) and human tissue specimens. Mouse models 
on hyperlipidemic backgrounds have been generated to disrupt 
one or more molecules that control the systemic immune sys-
tem. The worrying fact of the matter, however, is that – given 
the complex nature of the disease involving multiple genetic and 
life-style- and aging-driven risk factors – atherosclerosis research 
is in a dismal state.
Fundamental questions remain: the specific roles of each 
immune cell subset and their interplay, the timing and sites 
of their actions, the relative shares of the innate and adaptive 
immune systems in the organization of atherosclerosis immune 
responses over time, and the impacts and location of disease-
causing and disease-suppressing leukocyte subsets, all remain 
to be determined. The major challenge, however, concerns the 
principal nature of the underlying disease-causing immune 
responses: Is plaque formation a chronic autoinflammatory tis-
sue reaction (without generation of autoimmune B- or T-cells) or 
are elusive disease-causing autoantigens driving generation and 
action of autoimmune lymphocyte subsets?
Thus, atherosclerosis research shares major unanswered 
questions with other clinically important chronic inflammatory 
diseases such as rheumatoid arthritis, multiple sclerosis, and 
inflammatory bowel diseases (25–28). Based on circumstantial 
evidence, some of these diseases are considered bona fide auto-
immune diseases although – similar to atherosclerosis – their 
disease-triggering autoantigens have not been identified [see 
review in Ref. (23, 29, 30)]. Moreover, atherosclerosis-specific 
immune responses have long been assumed to be organized in 
atherosclerotic plaques in the intima layer of arteries or systemi-
cally in secondary lymphoid organs (SLOs), but the evidence for 
these views is scarce if not non-existing. Thus, it is safe to say that 
neither the existence, their nature (T- versus B-cell responses), 
nor the location of autoimmune reactions in atherosclerosis have 
been identified.
ATHeROSCLeROTiC PLAQUeS
The normal intima layer consists of an endothelial cell monolayer 
attached to the internal basement membrane (7). Vascular DCs 
have been described in the intima layer of normal mouse arter-
ies, but their role in the maintenance of artery homeostasis or 
their impact on disease has not been determined (31, 32). The 
disease ultimately affects all layers of the arterial wall including 
the media layer [largely consisting of vascular smooth muscle 
cells (VSMCs)] and the adventitial layer (the outer connective 
tissue coat; see below): advanced atherosclerosis can therefore be 
viewed as a chronic transmural inflammatory arterial wall disease. 
Early plaques undergo major alterations of cellular composition 
over time: during the early stages of the disease, subsequent or 
concomitantly with the influx of monocytes into the arterial wall, 
T-cells home into the intima. VSMCs may migrate into the intima 
and increase in number by self-renewal. Monocytes/macrophages, 
T-cells, and VSMCs undergo activation and proliferation during 
the various stages of the disease. It should be pointed out that 
other views on the early stages of atherosclerosis emphasize the 
role of platelets and/or neutrophils (12, 21).
STAGiNG OF ATHeROSCLeROSiS AND 
DiSTiNCT iMMUNe CeLL SUBSeTS iN 
ARTeRiAL wALL LAYeRS
Human atherosclerotic plaques have been staged into types I–VI 
according to the histological and clinical criteria (9). However, 
only the late V and VI stages become clinically significant when 
artery lumen narrowing compromises oxygen supply to the down-
stream tissue and the plaque becomes unstable. Atherosclerotic 
plaques in ApoE−/− mice recapitulate some – but not all – features 
of the different stages of human plaques. Of note, plaques lack 
B-cells and consequently B-cell follicles including follicular den-
dritic cells (FDCs). Plaques are also devoid of nerve axons, lymph 
vessels, high endothelial venules (HEVs), and lymph node-like 
conduits, which are all critically involved in efficient recruitment 
of lymphocytes and the subsequent organization of adaptive 
immune responses (see below) (Figures 1 and 2). It is therefore 
difficult to envision that immune cells in atherosclerotic plaques 
participate in adaptive cellular and humoral immune responses 
though they may be involved in antigen presentation to T-cells 
through vascular DCs or monocyte-derived DCs (mDCs) that 
emigrate from plaques to home to SLOs [see contribution of anti-
gen presentation by Hughes et al. (under review)1; this Research 
Topic].
1 Hughes C, Bedaj M, Benson RA, Maffia P. Antigen presenting cells and antigen 
presentation in tertiary lymphoid organs. (under review in this Research topic).
FiGURe 1 | Anatomy of the normal aorta adventitia and adjacent tissues. The normal adventitial layer of the mouse aorta constitutively contains T-cells  
(but no B-cells), tissue macrophages, cDCs, stromal cells or myofibroblasts, and mast cells. The adjacent tissues including the periaortic adipose tissue harbors 
fat-associated lymphoid clusters (FALCs) in wild-type mice. FALCs represent T/B-cell aggregates of various sizes that are exclusively observed in adipose tissue.  
In the adventitia, axons of both the sensory and the sympathetic nervous systems have been identified as well as vasa vasorum and lymph vessels. Ganglia of the 
peripheral nervous system are embedded in the adipose tissue, and their axons reach the external lamina that separates the adventitia from the media layer.
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THe ADveNTiTiA: AN eLUSive 
CONNeCTive TiSSUe COAT OF ARTeRieS
A commonly accepted notion states that the adventitia (33–37) 
forms the outer connective tissue coat that surrounds blood ves-
sels or arteries. Given the complexity of the connective tissue 
surrounding arteries and the lack of size definition together with 
recent progress in understanding the potential impact of the 
adventitia in arterial wall remodeling and atherosclerosis, the 
shortcomings of this definition are apparent (35). However, as we 
discuss below, the adventitia is a highly active and complex tissue 
whose roles in the maintenance and homeostasis of the artery is 
only beginning to be unraveled (38–50).
To delineate the impact the adventitia may have on arterial wall 
remodeling and atherosclerosis in future studies, a more sophis-
ticated definition should be attempted. The normal connective 
tissue coat surrounding arteries (in the mouse within 100 μm 
extending from the aorta external lamina separating the media 
from the adventitia) includes blood vessels (vasa vasorum), small 
lymph vessels, and an axon network of both the sympathetic and 
the sensory peripheral nervous systems (Figure 1).
Unlike the resistance arteries (muscular arterioles) involved 
in blood pressure regulation, axons of both of these peripheral 
autonomous nervous systems, but not of the parasympathetic 
nervous system, reach out to the external lamina; however, they 
do not cross into the media of medium- and large-sized arteries in 
mice. Major cellular constituents in the normal adventitia are mast 
cells, T-cells, and tissue macrophages, a meshwork of fibroblasts 
or myofibroblasts, classical DCs (cDCs), and most likely pericytes 
[see contribution of Kranich and Krautler (51); this Research 
Topic]. Furthermore, the adjacent adipose tissue (containing 
FALCs) needs to be considered as a tissue in the immediate vicinity 
of the adventitia (Figure 1). Thus, in mice, the immediate connec-
tive tissue coat within a diameter of 100 μm contains myofibro-
blasts, a loose network of extracellular matrix components, small 
blood and lymph vessels, and nerve axons. In addition, few tissue 
macrophages, T-cells, cDCs, and mast cells are important cellular 
constituents of the normal adventitia (33, 52) (Figure 1).
Each of these immune cell subsets may participate in immune 
surveillance of arteries (35, 53). Adventitia progenitor cells main-
tain the endothelial and VSMC pools (52). The vasa vasorum is 
a network of small blood vessels that reach the external lamina 
FiGURe 2 | Anatomy of the diseased aorta adventitia in aged hyperlipidemic mice. Aged hyperlipidemic mice develop ATLOs in the adventitia layer of the 
aorta selectively adjacent to atherosclerotic plaques with a preference for the abdominal aorta segment. ATLOs range from small T/B-cell aggregates to  
well-structured TLOs with separate T- and B-cell areas. The most advanced forms of ATLOs contain B-cell follicles including FDCs, newly formed conduits, HEVs, 
and aberrant lymph vessels (see Figure 4).
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providing nutrients and oxygen to large- and medium-sized arter-
ies (36, 38, 54, 55). Though little is known about their functional 
impact, conceivably, each of these adventitia constituents could 
affect arterial wall homeostasis. We have begun to systemati-
cally delineate the aorta adventitia of wild-type (WT) mice and 
hyperlipidemic ApoE−/− mice (Figures  1 and 2). The normal 
adventitia is neighboring the para-aortic adipose tissue, which 
contains FALCs recently described in the omentum of the perito-
neum of mice [(56); observations; contribution of Caamano et al. 
(under review)2; this Research Topic]. Although little is known 
about them in atherosclerosis, it is conceivable that FALCs may 
participate in atherosclerosis immune responses. It is important 
to distinguish each of the adventitia and adjacent tissues as it is 
recognized that cells in the adventitia and the adjacent tissues are 
capable of sensing and responding to a wide range of stimuli (37).
DiSCOveRY AND STAGiNG OF ATLOs
Tissues that are invaded by antigen are targeted by leukocytes 
which form – within hours – an acute form of inflammatory 
2 Caamano J et al. (manuscript in preparation for this Research topic).
infiltrate. This rapid and vigorous action of the innate immune 
system is carried out with the aim to eliminate the antigen before 
it can spread and/or inflict harm. However, if the immune sys-
tem fails to eliminate the invaders, the immune system doubles 
down on its efforts: the nature of the inflammatory infiltrate will 
change over time including a reduction of neutrophils, further 
recruitment of blood monocytes, de novo recruitment of T-cells 
and DCs and form – within days – a predominantly monocyte/
macrophage/T-cell/DC-driven inflammatory tissue response 
(57–59).
Can this type of immune cell infiltrate qualify as a TLO? It 
probably does or should not qualify for the following reasons: 
lymphorganogenesis during ontogeny and in adult organisms 
requires action of lymphorganogenic chemokines, i.e., CCL21 and 
CXCL13 (60, 61), which are essential for the attraction of B-cells 
and the formation of T/B-cell aggregates (various contributions 
in this Research Topic). Without lymphorganogenic chemokines, 
the immune system is severely impaired (60, 62). There may be 
exceptions to this paradigm as recent studies on colitis models 
in mice suggest that the nervous system is not only triggering 
the earliest forms of lymph node anlagen (63) but also TLO 
neogenesis in the gastrointestinal tract (64). In addition, early 
and chronic inflammatory infiltrates without major structural 
5Yin et al. ATLOs: Powerhouses of Atherosclerosis Immunity
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components of SLOs including HEVs, lymph vessels, and con-
duits, and T-cell areas and B-cell follicles may be less efficient in 
recruiting and activating naïve lymphocytes to generate T- and 
B-memory cells in response to antigen [(65); see Ruddle (under 
review)3; this Research Topic].
In 2004, we reported that the number of inflammatory 
leukocytes, in particular monocyte/macrophages and T-cells, 
when determined by morphometry of the innominate artery and 
throughout the arterial tree, increase progressively in the adven-
titia during aging (66). We systematically studied the relation 
between plaque and adventitial leukocytes in ApoE−/− mice that 
were adolescent/young (16 weeks; small atherosclerotic plaques), 
adult (32  weeks; significant atherosclerosis in the aortic arch; 
little atherosclerosis in the abdominal aorta); advanced adult 
(52 weeks; significant aortic arch atherosclerosis; beginning ath-
erosclerosis of the abdominal aorta), and aged (78 weeks; signifi-
cant atherosclerosis throughout the aorta including abdominal 
segments) (46).
The results of these studies can be summarized as follows: 
the inflammatory infiltrate of atherosclerotic plaques decreased 
in cellularity over time; by contrast, adventitial T-cells and mac-
rophages increased over time in adventitia segments areas that 
were afflicted with atherosclerosis throughout all major arteries; 
the size of the adventitial infiltrates correlated with atherosclerotic 
plaque burden in a highly territorialized way; the ratio between 
adventitia T-cell density over plaque T-cell density reached a 
dramatic approximately 80-fold in aged ApoE−/− mice in some 
segments (46); T-cells were both CD4+ and CD8+ T helper 
cells and also included a large T regulatory cell component (see 
below); the cellularity of the ubiquitous adventitial infiltrate in 
areas such as the innominate artery and the thoracic aorta could 
be distinguished from that in the upper abdominal portion of the 
aorta, however, which was being infiltrated by B-cells at around 
52  weeks of age. We therefore suggested that the lymphocyte 
aggregate of the earliest TLO stage (Stage I) should be character-
ized by a combined T-/B-cell aggregate. Stage I TLOs have not yet 
been fully separated T-cell and B-cell compartments, but they are 
precursors of the well-developed later artery tertiary lymphoid 
organ (ATLO) stages as indicated by kinetic experiments (41, 46). 
We suggested three stages of ATLOs.
ATLO Stage I: B-cells begin to infiltrate the adventitia as 
loosely arranged leukocytes without forming distinct T- and 
B-cell areas; ATLO Stage I emerges parallel to the formation 
of atherosclerotic plaques in the intima during aging and has 
not been observed in young mice; this first ATLO stage strongly 
indicates the action of lymphorganogenic chemokines, i.e., 
CCL21 and CXCL13, which may be important chemoattract-
ants for T- and B-cells, respectively, and thus ATLO neogenesis. 
It is noteworthy that not all adventitial leukocyte infiltrates 
adjacent to atherosclerotic plaques develop into ATLOs. In 
hyperlipidemic mice, ATLO Stage I, as all subsequent stages, has 
a strong preference for the upper abdominal aorta adventitia. 
3 Ruddle N. High endothelial venules and lymphatic vessels in tertiary lymphoid 
organs: characteristics, functions, and regulation. (under review in this Research 
topic).
However, we have little cues as to the molecular mechanisms for 
this predilection site. ATLO Stage II: separate T- and B-cell areas 
emerge; lymph vessel neogenesis becomes prominent together 
with a dense network of lymph node-like conduits connecting 
the arterial wall with newly formed HEVs. ATLO Stage III: a 
well-structured ATLO contains separate T-cell and B-cell fol-
licles with activated germinal centers (GCs) including FDCs, 
plasma cell (PC) niches, prominent lymph vessel, and blood 
vessel neogenesis of vasa vasorum.
It should be noted, however, that ATLO stages and the onset of 
lymph vessel, blood vessel, and HEV neogenesis have not yet been 
defined. Following this reasoning, TLO Stage II can be distin-
guished from Stage I by the development of separate T- and B-cell 
areas. Although TLO Stage II lacking FDCs does not appear to 
be able to mount affinity maturation of B-cell receptors (BCRs) 
in a GC reaction [see Kranich and Krautler (51); this Research 
Topic], it is likely that activation of T-cells and B-cells and somatic 
hypermutation of BCRs can be organized in ATLOs stages I and 
II (67, 68). Finally, TLO Stage III shows activated GCs contain-
ing FDCs in B-cell follicles as their defining hallmark (see also 
Figures 3 and 4).
Although not directly demonstrated for any TLO, it is conceiv-
able to assume that there is – at least for some TLOs – an antigen-
driven T-cell activation and memory T-cell generation pathway 
(69, 70). In addition, in Stage III TLOs, an affinity maturation 
pathway leading to memory B-cells and/or PC generation is likely 
to occur (see below). Our proposal of TLO staging in general and 
that of ATLO staging in particular is debatable from a number 
of perspectives and should be regarded as an exercise to begin a 
discussion on the pros and cons of these definitions.
Our rationale to define the TLO stage is as follows: ATLOs 
Stage I already harbors proliferating T- and B-cells, which appear 
to be vigorously activated (note that both T-cell and B-cell activa-
tion occurs or can occur outside of GCs and in the absence of 
FDCs to mount a protective and/or proinflammatory adaptive 
immune response); the emergence of CCL21 and CXCL13 signals 
as strong drivers of lymphorganogenesis (71–74); CCL21 and 
CXCL13 expression indicate – in adult organisms – the activa-
tion of the lymphotoxin receptor and the tumor necrosis factor 
receptor on lymphoid tissue organizer (LTo) cells, which appear 
to be required for differentiation of stromal cells to become LTo 
cells (41, 67, 75–77).
It is of interest to note that major underlying mechanisms 
of ATLO neogenesis are distinct when compared with similar 
structures in the lung. Inducible bronchus-associated lymphoid 
tissues (iBALTs) preferentially form in young mice, whereas 
well-developed ATLOs are not observed before the age of 
52 weeks (41, 78) [see article by Hwang et al. (79); this Research 
Topic]. However, there are also similarities, i.e., some iBALTs 
develop in the perivascular space of pulmonary blood vessels 
in addition to the connective tissue underneath the bronchial 
epithelium.
ATLO iMMUNe CeLLS AND STRUCTUReS
To understand atherosclerosis-related adaptive immune 
responses in the diseased arterial wall better, we determined 
FiGURe 3 | Hypothetical choreography for antigen-dependent ATLO T-cell response pathways. ATLOs are powerhouses of T-cell immunity. They promote 
T-cell recruitment and suppress T-cell egress allowing for extended T/DC interactions, activation, proliferation, and education of T-cells. ATLOs also mediate 
conversion of naïve CD4+ T-cells into iTreg cells. This schematic representation has been modified from Hu et al. reported earlier [see Ref. (67) for detailed data].
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leukocyte subtypes in the abdominal aorta during aging in 
ApoE−/− mice, which we had tentatively termed tertiary lym-
phoid follicles (46,  66). As the high leukocyte density in these 
developing follicles prevented morphometric analyses, we 
established single cell suspension protocols of aorta segments 
to perform FACS analyses (67): T-cell subtypes include CD4+, 
CD8+, FoxP3+ CD4+, and few FoxP3+ CD8+ cells; a significant 
number of B-cells accumulate in the follicles though B-cells 
are rarely seen in other parts of the arterial tree; no lymphoid 
follicles develop in plaque-free aorta segments; leukocyte fol-
licles are absent in young mice before 52  weeks of age; there 
is marked neogenesis of HEVs, lymph node-like conduits, and 
lymph vessels; the lymph vessels are aberrant in that they show 
dilated lumina with large numbers of luminal leukocytes; semi-
quantitative analyses revealed that the follicles promote recruit-
ment of T-cells after adoptive transfer through HEVs, whereas 
little recruitment occurs in atherosclerotic plaques; the conduits 
resemble lymph node conduits as they exclude fluorescent dex-
tran particles of 500 kDa (which were seen in the HEV lumen 
only) though they transport 10-kDa dextran particles; VSMCs 
in segments afflicted with atherosclerosis and lymphocyte fol-
licles in the adventitia express lymphorganogenic chemokines 
CCL21 and CXCL13; in  vivo blockade using an antagonistic 
decoy lymphotoxin β receptor antiserum eliminated FDCs from 
the aggregates and significantly reduced the number of HEVs 
(41). These data indicated that atherosclerosis is associated with 
TLO formation.
CONDUiTS, ANGiOGeNeSiS, 
LYMPHANGiOGeNeSiS, AND 
NeOFORMATiON OF Hevs
There is considerable information on the structure and function 
of conduits in SLOs (41, 63, 80–83). In SLOs, stromal cells in the 
subcapsular sinus of lymph nodes play a major role in the traffic of 
molecules and of distinct immune cells (65, 84). Although little is 
known about conduits in TLOs, we identified conduit-like struc-
tures in ATLOs using immunohistochemistry and fluorescent 
dextran labeling in vivo [(41); Figure 2]. We observed that ATLO 
conduits share a series of structural and cellular similarities of 
LN conduits. Moreover, using fluorescently labeled microbeads, 
we observed that ATLO conduits sieve low molecular weight 
molecules from the circulation into the conduit network (41). 
However, the normal lymph node conduits are structures that 
connect afferent lymph and HEVs.
This anatomy of lymph node conduits is probably different 
from that of ATLOs: in lymph nodes, conduits form a reticular 
network connecting the subcapsular sinus and HEVs [see Ager 
(under review)4; this Research Topic]. Instead, we found that ATLO 
conduits connect the outer media of the arterial wall with newly 
formed HEVs within the T-cell areas of ATLOs. This distinctive 
4 Ager A. High endothelial venules. (manuscript in preparation for this Research 
topic).
FiGURe 4 | Hypothetical choreography of antigen-dependent ATLO B-cell response pathways. Advanced ATLOs are powerhouses of B-cell immunity. 
ATLO B-cell responses are two-pronged in nature containing a comprehensive B-1 and a multi-faceted B-2 maturation pathway. Although similarities of B-cell 
immunity in ATLOs and SLOs are apparent, differences include a large PC component and a distinct B-1 B cell compartment which differs from that in the peritoneal 
cavity. This schematic figure has been modified from Srikakulapu et al. (68) [see Ref. (68) for detailed data].
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anatomy of conduits in SLOs versus TLOs is interesting in view of 
the hypothesis that chemokine gradients may exist within ATLOs 
with possible CXCL13 derived from activated media segments 
adjacent to atherosclerotic plaques. Furthermore, small molecular 
weight soluble antigens could be transported from the media to 
T-cell areas or B-cell follicles. It is possible that the lymph vessels 
of ATLOs also connect with conduits, but this has not yet been 
studied. We therefore speculate that molecules in the range of 
the size of chemokines (which can enter conduits) and possibly 
soluble antigen may be transported from the media compartment 
to HEVs, i.e., the entry sites of lymphocytes into ATLOs. Given 
the capacity of several ATLO antigen-presenting cells (APCs) to 
present exogenous antigen to T-cells [see contribution of Maffia 
et al. (33); this Research Topic], ATLO conduits may therefore have 
functional roles in the maintenance of atherosclerosis immunity.
However, ATLOs lack capsules and therefore no apparent 
subcapsular sinus, i.e., the anatomical structure that allows 
afferent lymph vessels to drain cells and antigen via conduits into 
the parenchyma of the lymph node. Although there are clearly 
differences in conduit architecture between lymph nodes and 
ATLOs, the function of the latter may be to facilitate draining 
of the inflamed artery to allow antigen access the T-cell areas of 
ATLOs. However, the precise function of ATLO conduits remains 
to be determined. It will be of interest to test the possibility 
whether the atherosclerosis immune response within the arterial 
wall may be altered by crossing ApoE−/− with PLVAP−/− mice that 
have a pathological conduit system (82).
ATHeROSCLeROSiS, AGiNG,  
AND ATLO T-CeLL iMMUNiTY
Our data on ATLOs raise several questions: Is aging of the 
immune system (also referred to as immune senescence) 
(85–87) affected by hyperlipidemia? What is the relationship 
8Yin et al. ATLOs: Powerhouses of Atherosclerosis Immunity
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 387
between local and systemic, i.e., SLO-dependent, atherosclerosis 
immunity during aging? Are there principal differences in T-cell 
immunity-related gene expression and inflammation-related 
gene expression in atherosclerotic plaques versus ATLOs? What 
is the territoriality of atherosclerosis T-cell responses in diseased 
arterial walls? (Figure  3) How are the ATLO T-cell responses 
organized as opposed to those in SLOs? Are VSMC lymphotoxin 
β receptors important in shaping the anatomy and function of 
ATLOs? Answers to these questions may be of general interest to 
understand TLO immunity in a wide range of disease conditions.
At the level of renal lymph nodes (RLNs) which drain the 
aorta, we characterized major T-cell subtypes during aging by 
FACS and genome-wide transcript expression arrays. Although 
the results of these studies identified major age-related gene 
expression changes, transcriptomes of WT versus ApoE−/− RLNs 
were principally identical (67), indicating that hyperlipidemia 
does not affect T-cells and their activation systemically in major 
ways including aorta-draining LNs. However, transcriptome 
analyses of RLNs, spleen, and blood during aging showed marked 
aging/senescence-dependent changes. In sharp contrast, immune 
response-related and inflammation-related changes in aorta ter-
ritories, i.e., plaques versus ATLOs, were dramatic, indicating that 
T-cell immunity in atherosclerosis appears to be regulated locally 
rather than systemically (67).
We used laser capture microdissection-based mRNA expres-
sion analyses to construct transcript atlases and to delineate the 
territoriality of T-cell immunity in the arterial wall in comparison 
with SLOs. Gene ontology (GO) terms immune response, inflam-
mation, T-cell activation, positive regulation of T-cell regulation, 
and T-cell proliferation were examined. Again, these analyses 
failed to identify significant differential gene expression in WT 
versus ApoE−/− RLNs (2 genes), but major changes between RLNs 
and ATLOs (1251 genes), between atherosclerotic plaques and 
ATLOs (1102 genes), and major changes between adventitia seg-
ments afflicted with versus those without atherosclerotic plaques 
in the intima (1274 genes). The transcript atlases of ATLOs 
and other affected diseased tissues in atherosclerosis (88,  89) 
will be important to address a variety of questions regarding 
atherosclerosis immunity and other issues including remodeling 
of extracellular matrix components during disease progression. 
The data were published in the NCBI Gene Expression Omnibus 
(GSE 40156) to be used to address a series of questions such as 
B-cell immunity in the arterial wall [see Ref. (68); below].
T-CeLL PHeNOTYPeS iN ATLOs ARe 
DiSTiNCT FROM THOSe iN SLOs
FACS analyses yielded additional information on the activation 
status of ATLO T-cell subtypes: naïve T-cells were rare in ATLOs 
yielding a 27-fold ratio of ATLO CD4+ T effector memory cells 
(TEM) and also considerable numbers of T central memory (TCM) 
T-cells over their naïve counterparts; similar data were obtained 
for T regulatory cells (Treg cells) yielding an 87-fold ratio of Treg 
cells with an EM or CM phenotype over their naïve counterparts, 
and in a similar, though less pronounced, way, the data were 
similar for CD8+ T-cells. Functional impacts of TLOs in general 
and of ATLOs in particular are only beginning to be understood. 
In peripheral tissues, immunosurveillance is carried out by 
tissue-specific homing and education of TEM and TCM T-cells as 
exemplified in skin and intestine (90–97). Thus, T-cells home 
into inflamed tissues, but they are also retained in these tissues 
to account for preferential action of T-cells in the diseased versus 
healthy tissues.
To study T-cell tropism in atherosclerosis, a series of adop-
tive transfer experiments were conducted to test the ability of 
ATLOs as homing hubs and education centers of T-cell immunity. 
Sizable numbers of ATLO CD4+, CD8+, and Treg cells expressed 
CD103, PD-1, CD69, and other activation and homing molecules 
contrasting to their SLO counterparts. Moreover, there were 
little changes in these T-cell education signatures in WT versus 
ApoE−/− SLOs. As T-cell recirculation is rapid, we used adoptive 
transfers using highly FACS-purified naïve T-cells in splenecto-
mized and FTY720-treated mice: splenectomy was necessary to 
prevent recirculation of T-cells through the spleen, while FTY720 
was required to prevent T-cell egress from lymph nodes. These 
data showed that ATLOs are effective in both recruitment and 
preventing egress of T-cells. FTY720 acts through sphingosine 
1-phosphate receptors type 1 expressed by efferent lymph vessel 
endothelial cells in SLOs (98, 99). Our data also indicated that 
ATLO lymph vessels are functional and therefore may be involved 
in T-cell recruitment and recirculation into and out of the arterial 
wall bearing strong similarities to the function of lymph vessels in 
lymph nodes (67) (See text footnote 3).
Leukocyte movement in ATLOs versus WT adventitia was 
also assessed using multiphoton microscopy. These data showed 
striking similarities of T-cell movement that had been observed 
when naïve T-cells undergo a primary immune response in SLOs 
during activation and priming including length of migration per 
time interval, track velocity, and displacement (67, 100–102). 
In contrast, movement parameters of naïve T-cells in the WT 
adventitia showed nearly motionless cells. Detailed studies of 
movement parameters of T-cells in WT versus ApoE−/− lymph 
nodes including the popliteal lymph node which does not drain 
the aorta showed identical characteristics. Furthermore, we 
identified a series of APCs in ATLOs using two independent 
assays of in vivo antigen presentation [see article of Maffia et al. 
(33); this Research Topic]. The composition of ATLO APCs, 
however, was aberrant in that the majority was mDCs followed 
by B-cells, cDCs, macrophages, and a minor population of 
lymphoid DCs (lyDCs).
ATLOs CONTAiN LARGe NUMBeRS OF  
T ReGULATORY CeLLS AND CONveRT 
NAÏve T-CeLLS iNTO iNDUCeD  
T ReGULATORY CeLLS
T-cell-specific ATLO immunity is dichotomic in nature in that 
both proinflammatory and anti-inflammatory lymphocyte 
subsets including a large number of Treg cells have been observed 
using immunohistochemistry and FACS analyses (41, 103). It 
is well established that Treg cells accumulate in inflamed tissues 
(104–106). There are two major Treg subtypes, i.e., one that is 
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generated in the thymus (nTreg cells) and another that is gener-
ated in the periphery from naïve CD4+ precursors (105) termed 
induced Treg (iTreg) cells. The functional significance of these two 
Treg subtypes for the regulation of T-cell immunity in various 
diseases remains to be fully understood, but it is possible that 
the TCR repertoire of naïve CD4+ T-cells gives rise to memory 
Treg cells that have potent immunosuppressive properties under 
chronic inflammatory disease conditions as judged from other 
model systems in mice (105, 107). Moreover, regulatory T 
memory cells have been identified and may contribute to antigen-
specific immunosuppression (108).
In view of our observation that ATLOs contain large numbers 
of Treg cells (41), we attempted to characterize ATLO Treg cells 
in more detail using subtype-specific markers and to delineate 
the activation status of ATLO Treg cells. Naïve GFP-Treg cells 
purified from spleens and lymph nodes of transgenic FoxP3-
DTR-GFP mice (106) were adoptively transferred into aged 
ApoE−/− mice and their phenotype was examined in ATLOs. 
The adoptively transferred Treg cells did not show the activated 
endogenous phenotype even 3 weeks after transfer. These data 
were surprising and indicated that the endogenous ATLO Treg 
cell population may be generated locally through an extended 
period of time during aging and that there may be clonal selec-
tion of endogenous Treg cells in an antigen-specific way (67). We 
then examined the ability of ATLOs to convert CD4+ T-cells into 
iTreg cells. FACS-purified naïve CD4+ T cells were transferred 
into aged ApoE−/− mice. Although at 24 h, ATLOs did not show 
significant iTreg cells, after 3 weeks, a considerable number of Treg 
cells in ATLOs became Helios−/FoxP3+ iTreg cells consistent with 
the ability of ATLOs to generate Treg cells from CD4+/FoxP3− 
precursors in the periphery (67).
ATLO B-CeLL SUBSeTS iNDiCATe 
ANTiGeN-SPeCiFiC HYPeRMUTATiON, 
AFFiNiTY MATURATiON, AND iSOTYPe 
SwiTCHiNG iN ATLO GCs
We explored aorta B-cell immunity in aged ApoE−/− mice 
(Figure  4). Inspection of B-cell-related aorta transcriptomes 
(see above) revealed large numbers of differentially expressed 
transcripts in the GO terms B-cell-mediated immunity, B-cell 
activation, positive regulation of B-cell-mediated immunity, posi-
tive regulation of B-cell activation, B-cell proliferation, and B-cell 
differentiation during aging (68). At the systemic immune system 
level, aging was associated with large numbers of age-dependent 
differentially expressed B-cell-related transcripts, but no major 
changes were observed in B-cell-related transcripts when WT 
and ApoE−/− SLOs or blood were compared. These data demon-
strated that the systemic B-cell transcriptome underwent strong 
aging/senescence-specific changes but that hyperlipidemia did 
not affect these changes.
B-cell-related transcripts of whole aortas specifically 
emerged during the time window of 52–78 weeks correlating 
with the appearance of ATLOs. Bona fide B-cell genes, such 
as IgM transcripts, were induced by a factor of up to 135. In 
sharp contrast, young WT or young ApoE−/− aortas did not 
express B-cell genes as confirmed by immunohistochemistry. 
Furthermore, we never observed B-cells in atherosclerotic 
plaques either in the thoracic or abdominal aortas at any 
age using a variety of marker antibodies. However, as small 
lymph nodes lining the adventitia contained large numbers of 
B-cells, the FACS analyses – but not the immunohistochemical 
analyses – showed few B-cells indicating that the preparations 
of single cell suspensions from aortas were contaminated by 
lymph node-derived B-cells (109).
Laser capture microdissection-derived transcriptome atlases 
were constructed from distinct aorta tissues. Genes associated 
with B-cell survival, proliferation, differentiation, and activation 
were expressed in ATLOs including immunoglobulin genes, 
TACI (tnfrsf13b), B-cell activating factor receptor (tnfrsf13c), 
CD40 antigen (cd40), complement components (c1qb), and 
myD88 (68). The degree of territoriality of adventitial B-cell 
transcripts was high as adventitial tissues adjacent to adventitia 
segments that were not afflicted with atherosclerotic lesions 
in the intima and did not or to a much lesser extent expressed 
these genes. Moreover, the igj chain gene involved in somatic 
hypermutation of the BCR, and B-cell memory cell generation 
(110) was expressed at a significant level in ATLOs. Expression of 
B-cell-related genes in the atherosclerotic plaque versus ATLOs 
showed marked differences: bona fide B-cell genes showed strong 
expression in the adventitia versus low expression in plaques 
[ighm; cd19; ms4a1 (CD20), igj, and cd79a/b], whereas athero-
sclerotic plaques expressed inflammation-related B-cell-related 
genes that are expressed in B-cell target cells including mac-
rophages. As expected from the global comparisons between WT 
and ApoE−/− RLNs, no differential expression of B-cell-related 
genes were observed though – as pointed out above – aging/
senescence was significant. We determined B-cell subtypes using 
an improved protocol to prepare single cell suspensions for FACS 
analyses (109).
HeTeROGeNeOUS B-CeLL SUBTYPeS  
iN ATLOs veRSUS LYMPH NODeS  
AND SPLeeN
B-cell subtype data indicated three distinct major B-cell subtypes: 
B-2 cells, B-1 cells, and PCs. B-2 B-cell subtypes contained IgM+/
IgD− (immature or transitional B-cells are either immature 
B-cells that have left the bone marrow or they represent B-1 cells), 
IgM+/IgD+, and IgM−/IgD+ B-cells (mature B-cell maturation 
stages). Among mature IgD+ B-cells, IgM−/IgD+ B-cells represent 
follicular B-2 cells. IgM−/IgD− cells represent either switched Ig+ 
B-cells, GC B-cells that have transiently lost Ig expression during 
somatic hypermutation of their Ig genes or they are GC memory 
B cells. Of special interest regarding impacts of ATLOs to control 
B-cell immunity was the identification of GC B-cells, i.e., IgD−/
PNA+/GL-7+ B-2 cells, indicating GC reactions (somatic hyper-
mutation and affinity maturation). These data indicated that 
ATLOs conduct the entire B-cell maturation pathway including 
antigen-specific B-cell GC reactions. Furthermore, we sought 
evidence for isotype switching within ATLOs, which follows the 
GC reaction in SLOs. We observed CD19+/IgD−/IgG1+, CD19+/
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IgD−/IgA+, and CD19+/IgD−/IgE+ B-2 cells in ATLOs. Although 
class switching is not restricted to GCs, the totality of our mor-
phological, transcript atlas transcriptome, and FACS analyses are 
consistent with the possibility that class switching follows ATLO 
GC reactions (68).
PCs FORM A LARGe ATLO  
B-CeLL SUBSeT
We had observed earlier that ATLOs contain PCs in the periph-
ery adjacent to T-cell zones (41). PCs constitute a major part of 
B-cell memory (29, 111, 112): two major PC subtypes had been 
identified in SLOs, i.e., the short-lived and long-lived PCs (113, 
114), whereby short-lived PCs – after their generation – home 
to SLOs, whereas long-lived PCs largely home to the bone mar-
row. Both PC subtypes were identified in ATLOs using a BrdU 
labeling protocol (68). As it is known that PCs use inflammatory 
tissues as survival niches, our data fall short of demonstrating 
the generation of short-lived or long-lived PCs within ATLOs. 
Further work needs to address the important question where 
the ATLO PCs are generated and whether they provide B-cell 
memory that is atherosclerosis antigen-specific or whether they 
merely reflect the influx of atherosclerosis-unrelated PCs into the 
inflammatory arterial wall adventitia. In attempts to determine 
the potential functions of the arterial wall PCs, we determined 
their marker profile: a fraction of them express IL-10 indicating 
that at least some of them exert immunosuppressive activities. 
The second major B-cell subtype was B-1 cells. Two major 
observations deserve attention: (i) The B-1 cell subtypes, unlike 
their peritoneal cavity counterparts, were skewed toward B-1b 
cells versus B-1a cells. (ii) As the two B-1 subtypes have different 
functions to contribute to T-cell-independent B-cell immunity, 
further studies are needed to determine the functional impact of 
each of these subtypes to contribute to atherosclerosis immunity. 
As many of the ATLO B-1 cells express markers of immunosup-
pressive B regulatory cells (115–121) (TGFβ1, IL-10, PD-L1, 
and FasL), it is conceivable that the majority of B-1 cells have 
anti-atherosclerosis impacts on the disease.
eXPLORATiON OF TLOs: TRiCKS AND 
DeLUSiONS AROUND eveRY CORNeR
As potential roles of TLOs in an expanding number of clinically 
important diseases are being recognized, robust methods for 
their exploration need to be established. ATLOs are among the 
best characterized TLOs in any disease: however, they are located 
in a complex tissue environment (see above) which asks for a 
combination of analytical techniques to avoid methodological 
flaws. Analyses of ATLOs – let alone other TLOs – pose consider-
able challenges: their formation occurs at inconsistent rates and 
variable sizes; ATLOs’ structures and cellular compositions range 
from small T/B lymphocyte aggregates to large lymphoid clusters 
containing distinct T-cell areas, B-cell follicles including activated 
GCs, and PC niches; similar to the dichotomic nature of SLOs, 
ATLOs generate both effector and immunosuppressive T and B 
lymphocytes; boundaries between ATLOs and other periaortic or 
perivascular tissues are difficult to define: they are located close 
to numerous small paraaortic lymph nodes, periaortic adipose 
tissue compartments, and ganglia of the sympathetic nervous 
system (Figure 1).
It is important to note: very little is known about these previ-
ously overlooked lymphoid aggregates (122). Consequently, 
major questions arose soon after they had been discovered: 
how to define a TLO? Should small T/B aggregates qualify as an 
early stage of a TLO or is the presence of FDCs in GCs essential 
to qualify a lymphocyte aggregate as TLO? How to distinguish 
between bona fide TLO cells and cells of neighboring tissues 
if tissue borders of the unencapsulated TLOs are ill-defined? 
Other challenges relate to determination of the size of TLOs, 
define the molecular cues of their interaction with the adjacent 
diseased tissue, determine their specific cellular constituents, 
quantify and determine the activation status of their immune 
cell subsets, characterize the properties and gene expression 
signatures of their connective tissue mesenchymal cells, and 
most importantly examine their functional impact on disease 
progression.
Analyses so far applied to ATLOs include laser capture 
microdissection-based large-scale microarray analyses. This 
method has been shown valuable to understand the territorial-
ity of atherosclerosis-specific immune cells (41, 46, 67, 68, 88, 
89, 109). If combined with immunohistochemical analyses and 
FACS analyses, it provides guidelines and specific informa-
tion on many aspects of ATLO immunity. We have applied 
this technique to identify specific features of atherosclerosis 
immunity including lymphocyte activation and proliferation 
and the relation between artery immune responses and those 
in the draining RLNs. When carefully applied, laser capture 
microdissection-based mRNA expression analyses have helped 
to construct transcript atlases of both B-cell and T-cell immunity 
from which a series of conclusion can be drawn. These include 
lack of differential transcript expression in WT versus ApoE−/− 
RLNs, a large inflammation-related transcriptome in ATLOs 
when compared to the RLN, lack of bona fide B-cell genes in 
plaques, and differences in gene expression in adventitia with 
atherosclerotic plaque versus adventitia without plaque. Another 
important technique applied to ATLOs has been FACS analyses 
together with morphometric assays to quantify distinct lym-
phocyte subsets and their activation status. However, when we 
performed comparative analyses of aorta single cell suspensions 
and immunofluorescent microscopy analyses, we became aware 
of distinct shortcomings of FACS analyses: since the adventitia 
or by the same token ATLOs are not visible with the naked eye, 
there was a tendency to detect immune cell subsets including 
B-cells in WT adventitia that were undetectable by immunohis-
tochemistry indicating contamination of TLO preparations by 
neighboring tissues including FALCs.
ARe ATLOs ATHeROSCLeROSiS 
PROTeCTive? NOT SO FAST!
In the past, TLOs have often been viewed as disease-promoting 
aggregates of immune cells largely because TLOs were exclusively 
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disease-associated and because their size correlated with disease 
severity (123–126). However, as the immune cell composition 
of TLOs is being evaluated, concepts regarding their impact on 
disease have changed: it has been shown that immunosuppressive 
immune cells including Treg cells, B-1 cells, and innate immune 
cells are major TLO constituents (Figures 1–4).
As mentioned above, we observed that VSMCs that are sand-
wiched between aorta atherosclerotic plaques and ATLOs express 
the lymphorganogenic chemokines, i.e., CCL21 and CXCL13. As 
these chemokines are both indispensable and sufficient to organ-
ize lymph nodes and TLOs [see contribution by Watanabe (127); 
this Research Topic], we hypothesized that VSMCs may adopt 
features of LTo cells. In cultured aorta VSMCs, we observed that 
a combination of TNF and agonistic antibodies directed against 
the lymphotoxin β receptor, but not each cytokine alone, led to 
a strong induction of CXCL13 mRNA and protein (77). To test 
the hypothesis that CXCL13 expression in VSMCs affects ATLO 
homeostasis, we generated ApoE−/−Ltbrfl/flTagln-cre mice using 
the late VSMC differentiation marker, i.e., Tagln/SM22α (67, 
128). Unlike their Ltbr−/− counterparts, ApoE−/−Ltbrfl/flTagln-
cre mice showed no major alteration of the systemic immune 
system, indicating that the deletion of the Ltbr was specific for 
VSMCs. At the level of the arterial wall, however, ApoE−/−Ltbrfl/
flTagln-cre mice showed two distinct phenotypes when compared 
to their ApoE−/− controls: their ATLO structure was disrupted as 
evidenced by smaller ATLOs, less HEVs, loose mixed T-/B-cell 
aggregates rather than separate T- and B-cell areas; and the mice 
showed marked exacerbation of atherosclerosis. We interpreted 
these combined results as evidence that the VSMC lymphotoxin 
β receptor may be involved in atherosclerosis protection via 
ATLOs (67).
There are several caveats, however, regarding the veracity 
of this conclusion: VSMCs are also constituents of athero-
sclerotic plaques and the VSMC lymphotoxin β receptor may 
have affected atherosclerosis directly rather than via ATLOs; 
the mechanisms of an apparent atherosclerosis protection by 
ATLOs is complex as immunosuppressive leukocyte subsets 
have been described including Treg cells (67) and a series of 
IL-10+ B regulatory cells (68). It is therefore possible that the 
promotion of atherosclerosis in ApoE−/−Ltbrfl/flTagln-cre mice 
is due to mechanisms other than via ATLO’s impact on the 
disease and that – under different conditions – ATLOs may even 
promote the disease. What these conditions may be will be a 
subject of future studies, but it could either include activation of 
the various effector lymphocyte subsets that have already been 
described to be major cellular constituents of ATLOs or the gen-
eration of autoimmune lymphocytes. Yet, we have shown – as 
a proof of principal experiment – that interference with the 
lymphotoxin β receptor in presumptive tissue-specific LTo cells 
is an experimentally feasible approach and that this interference 
has an effect on the outcome of the associated disease. Similar 
approaches could lead to interference with the lymphotoxin β 
receptor in lymphoid tissue-organizer-like cells in other disease 
models if the receptor can be targeted specifically as shown for 
the Tagln/SM22α gene.
CHALLeNGeS AHeAD
We still do not know much about the specific impacts of any 
TLO on disease progression. Data from the characterization of 
the dichotomic nature of TLO immunity suggest that there is 
not a black or white picture: like SLOs, TLOs generate opposing 
immune responses that promote generation of antigen-specific 
lymphocyte subsets. Following this reasoning, it is probably naïve 
to give or ask for only one answer to this important question. 
However, we assume that the initial purpose of TLO neogenesis 
is to eliminate antigen and/or fight inflammation but whether and 
when the TLO turns into autoimmune responses and/or disease 
is – at present – difficult or impossible to assess. Analyses of the 
inflammatory cytokine/chemokine environment of TLOs and 
its chronicity versus the transient nature of antigen presentation 
in SLOs may yield additional distinguishing features of TLOs to 
examine their specific disease impacts.
Other distinguishing features of TLOs relate to the charac-
terization of PC niches, the analysis of innate lymphoid cells, the 
composition and impact of the macrophage phenotypes in TLOs, 
and last but not least the T-cell receptor and BCR repertoire of 
TLOs versus those of SLOs. One approach to identify the specific 
impact of TLOs in disease may be to delete the lymphotoxin β 
receptor in presumptive LTo cells as exemplified for ATLOs in 
atherosclerosis.
Although it seems clear from TLO research during recent 
years that disease-associated lymphoid clusters are power-
houses of disease immunity, new experimental approaches are 
needed. These include next-generation sequencing, specific 
tissue-targeted disruption of the lymphotoxin β receptor or of 
lymphorganogenic chemokines, improved methods to identify 
potential antigen-specific lymphocytes, a better understanding 
and characterization of iTreg cells, isolation of B memory cells 
and PCs, and cloning of their immunoglobulin genes. It will be 
of utmost interest to study tolerance mechanisms in TLOs. If 
TLOs fail to maintain tolerance, autoimmune lymphocytes are 
likely to be generated in them, which may have major implica-
tions for disease immunity. Understanding TLO immunity 
better may lead the way to exploit the amazing ability of the 
immune system to target disease mechanisms by developing 
immunotherapeutics for both chronic autoinflammatory and 
autoimmune diseases.
CONCLUSiON
Artery tertiary lymphoid organs are complex atherosclerosis- 
associated lymphoid aggregates that generate dichotomically 
acting immunosuppressive and immune response-promoting 
immune cells. Their structural organization and cellular com-
position suggest three major pillars of disease immunity: a large 
inflammatory component, a considerable antigen-independent 
element, and a possible antigen-specific domain. ATLO struc-
tures promote immune responses by recruitment of naïve 
lymphocytes, impaired egress, and extended DC/lymphocyte 
cluster formation. Until today, although many TLOs occur in 
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